Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses

BackgroundOncolytic viruses represent a novel form of cancer immunotherapy. Vaccinia viruses encoding human T cell co-stimulatory molecules have demonstrated clinical activity in phase I clinical trials in patients with advanced melanoma. However, predictive biomarkers of therapeutic response have not yet been identified.MethodsA customized microarray was performed to identify changes in peripheral blood mononuclear cell (PBMC) gene expression upon exposure to recombinant oncolytic vaccinia viruses. Up-regulated and down-regulated genes were identified and selected for further analysis using PBMC samples from normal donors and oncolytic virus-treated patients before and after viral injection. Quantitative PCR and flow cytometry of defined T cell subsets was performed to evaluate expression patterns and clinical correlations.ResultsThe microarray identified 301 genes that were up-regulated and 960 genes that were down-regulated in T cells after exposure to oncolytic vaccinia virus. The B7.1 gene was highly up-regulated and the immunoglobulin-like transcript 2 (ILT2) gene was highly down-regulated by vaccinia-B7.1, which was consistent with the known inverse regulation of these two genes. We observed an inverse association between ILT2 expression in the tumor microenvironment and clinical response and further identified ILT2 as a marker of regulatory CD4+ and suppressor CD8+ T cell responses and whose down-regulation was predictive of therapeutic responses in patients treated with oncolytic virus immunotherapy.ConclusionsILT2 is a new putative biomarker of T cell and clinical response in patients treated with oncolytic vaccinia virus immunotherapy. Further confirmation of ILT2 as a biomarker requires prospective validation in a larger series of clinical trials.

• Publication year

  2014

• Venue

  Journal of Immunotherapy for Cancer

• Publication date

  2014-01-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/2051-1426-2-1PMID 24829758PMCID 4019911
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncolytic virus therapy for cancer.

  2013cited by this paper
• Therapeutic Implications of KIT in Melanoma

  2012cited by this paper
• Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.

  2012cited by this paper
• Causes and Consequences of MicroRNA Dysregulation

  2012cited by this paper
• The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

  2011cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

  2009cited by this paper
• Oncolytic viruses for cancer treatment

  2009cited by this paper
• Human Inhibitory Receptor Immunoglobulin-Like Transcript 2 Amplifies CD11b+Gr1+ Myeloid-Derived Suppressor Cells That Promote Long-Term Survival of Allografts

  2008cited by this paper
• HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation.

  2007cited by this paper
• Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients1

  2007cited by this paper
• Local Delivery of Vaccinia Virus Expressing Multiple Costimulatory Molecules for the Treatment of Established Tumors

  2006cited by this paper
• Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

  2006cited by this paper
• Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function

  2006cited by this paper
• Polarized monocyte response to cytokine stimulation

  2005cited by this paper
• Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

  2005cited by this paper
• Poxviruses and immune evasion.

  2003cited by this paper
• Negative regulation of immunoreceptor signaling.

  2002cited by this paper
• Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4

  2002cited by this paper
• High-fidelity mRNA amplification for gene profiling

  2000cited by this paper
• Regulation of immune responses through inhibitory receptors.

  1999cited by this paper
• HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance.

  1998cited by this paper
• A Common Inhibitory Receptor for Major Histocompatibility Complex Class I Molecules on Human Lymphoid and Myelomonocytic Cells

  1997cited by this paper
• A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules.

  1997cited by this paper

• Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms

  2025cites this paper
• The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review

  2024cites this paper
• Oncolytic Viruses in the Era of Omics, Computational Technologies, and Modeling: Thesis, Antithesis, and Synthesis

  2023cites this paper
• The multifaceted role of MUC1 in tumor therapy resistance

  2022cites this paper
• Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic

  2022cites this paper
• Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways

  2022cites this paper
• Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment

  2022cites this paper
• Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients

  2022cites this paper
• Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements

  2022cites this paper
• Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response

  2021cites this paper
• Tumor infiltrating and peripheral CD4+ILT2+ T cells are a cytotoxic subset selectively inhibited by HLA-G in clear cell renal cell carcinoma patients.

  2021cites this paper
• Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice.

  2021cites this paper
• Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway

  2020cites this paper
• Oncolytic virotherapy: Challenges and solutions.

  2020cites this paper
• Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma

  2019cites this paper
• CD47 blockade augmentation of Trastuzumab antitumor efficacy dependent upon antibody-dependent-cellular-phagocytosis.

  2019cites this paper
• Optimizing oncolytic virotherapy in cancer treatment

  2019cites this paper
• The Antitumor Effect of Xihuang Pill on Treg Cells Decreased in Tumor Microenvironment of 4T1 Breast Tumor-Bearing Mice by PI3K/AKT~AP-1 Signaling Pathway

  2018cites this paper
• Plasma circulating tumor DNA as a potential tool for disease monitoring in head and neck cancer

  2018cites this paper
• Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model

  2017cites this paper
• Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade

  2017cites this paper
• PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells

  2017cites this paper
• Global dynamics of a colorectal cancer treatment model with cancer stem cells

  2017cites this paper
• Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy

  2017cites this paper
• Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives

  2017cites this paper
• Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy

  2017cites this paper
• Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach

  2017cites this paper
• Targetless T cells in cancer immunotherapy

  2016cites this paper
• Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.

  2016cites this paper
• Optimising Reovirus Type 3 Dearing (Reolysin®) as an anti-cancer therapeutic

  2016cites this paper
• Toll-like Receptors in the Vascular System: Sensing the Dangers Within

  2016cites this paper
• Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy

  2016cites this paper
• Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

  2016cites this paper
• Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment

  2016cites this paper
• Immunomonitoring in glioma immunotherapy: current status and future perspectives

  2016cites this paper
• Natural Killer Cell Recognition of Melanoma: New Clues for a More Effective Immunotherapy

  2016cites this paper
• Trial Watch—Oncolytic viruses and cancer therapy

  2016cites this paper
• OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

  2015cites this paper
• Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

  2015cites this paper
• Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis

  2015cites this paper
• Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

  2015cites this paper
• Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines

  2015cites this paper
• Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

  2015influential citation
• Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.

  2015cites this paper
• Trial Watch:

  2014cites this paper